Bart, Pierre-Alexandre and Goodall, Ruth and Barber, Tristan and Harari, Alexandre and Guimaraes-Walker, Ana and Khonkarly, Mona and Sheppard, Neil C. and Bangala, Yolanda and Frachette, Marie-Joelle and Wagner, Ralf and Liljestrom, Peter and Kraehenbuhl, Jean-Pierre and Girard, Marc and Goudsmit, Jaap and Esteban, Mariano and Heeney, Jonathan and Sattentau, Quentin and McCormack, Sheena and Babiker, Abdel and Pantaleo, Giuseppe and Weber, Jonathan (2008) EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade CHIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. VACCINE, 26 (25). pp. 3153-3161. ISSN 0264-410X,
Full text not available from this repository. (Request a copy)Abstract
NYVAC-C (vP2010), a recombinant vector expressing HIV subtype C gag, pot, env and nef antigens, was tested in a phase I study in healthy, HIV negative volunteers in London and Lausanne. Twenty-four participants were randomised to receive NYVAC-C (20) or matching placebo (4) at weeks 0 and 4, and assessed for safety and immunogenicity over 48 weeks. There were no serious adverse events, and no clinical or laboratory abnormalities or other events that led to withdrawal, interruption or dose reduction of the NYVAC-C/placebo. Half of the 10 assessed responded in the ELISpot assay under stringent criteria, which informed the sample size for a DNA-NYVAC-C comparison to NYVAC-C alone. (C) 2008 Elsevier Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | IMMUNOGENICITY; SAFETY; VIRUS; HIV preventative vaccine; NYVAC-C; phase I |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Oct 2020 09:55 |
| Last Modified: | 29 Oct 2020 09:55 |
| URI: | https://pred.uni-regensburg.de/id/eprint/30738 |
Actions (login required)
 |
View Item |
